

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/41, C07D 271/113		A1	(11) International Publication Number: WO 99/38510
			(43) International Publication Date: 5 August 1999 (05.08.99)
(21) International Application Number: PCT/US99/00910		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 15 January 1999 (15.01.99)			
(30) Priority Data: ① 60/072,966 ✓ 29 January 1998 (29.01.98) ✓ US ✓ ② 60/102,274 ✓ 29 September 1998 (29.09.98) ✓ US ✓			
(71) Applicant: ① BRISTOL-MYERS SQUIBB COMPANY [US/US]; 5 Research Parkway, Wallingford, CT 06492-7660 (US).		Published With international search report. /	
(72) Inventors: ① HEWAWASAM, Piyasena; 31 Brookview Lane, Middletown, CT 06457 (US); ② DING, Min; 78 Chase Hollow Lane, Glastonbury, CT 06033 (US). STARRETT, John, E., Jr.; 23 Hawks Nest Circle, Middletown, CT 06457 (US) / ③		200003766-3	
(74) Agent: ALGIERI, Aldo, A.; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492-7660 (US).		22 SEP 2000	
(54) Title: DERIVATIVES OF 1,3,4-OXADIAZOLONE ✓			
2 PDS. 1 applⁿ 3 Invs. IPC: A61K31/41 C07D271/113 IPER 13/7/99			
(I)			
(57) Abstract			
The present invention provides novel oxadiazolone derivatives having general formula (I), wherein A, B, D and R are as defined herein, or a nontoxic pharmaceutically acceptable salt or solvate thereof and are useful in the treatment of disorders which are responsive to the opening of the large conductance calcium-activated potassium channels.			